Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:20 PM
Ignite Modification Date:
2026-03-26 @ 3:20 PM
NCT ID:
NCT07374302
Eligibility Criteria:
Inclusion Criteria
* Adults aged 18 years or older.
* Confirmed diagnosis of pulmonary arterial hypertension (Group 1).
* Treatment with triple therapy including an endothelin receptor antagonist, a prostacyclin pathway agent, and a phosphodiesterase-5 inhibitor for at least 12 weeks.
* Switch from a phosphodiesterase-5 inhibitor to riociguat as part of routine clinical care.
* Availability of minimum data to assess the primary outcome at 6 months.
Exclusion Criteria
* Concomitant use of phosphodiesterase-5 inhibitors and riociguat.
* Inability to confirm vital status or hospitalization outcomes within 6 months.
* Participation in an interventional clinical trial that mandated the treatment switch.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07374302
Study Brief:
Protocol Section:
NCT07374302